

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/H13E0C1F162AEN.html>

Date: April 2022

Pages: 527

Price: US\$ 2,500.00 (Single User License)

ID: H13E0C1F162AEN

Abstracts

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma - Drugs In Development, 2022, provides an overview of the Hodgkin Lymphoma (Oncology) pipeline landscape.

Hodgkin lymphoma is a cancer that starts in white blood cells called lymphocytes. Symptoms include painless swelling of the lymph nodes in the neck, armpits, or groin, fever and chills, night sweats, weight loss, loss of appetite and itchy skin. Hodgkin lymphoma is most common among people ages 15 to 35 and 50 to 70. Past infection with the Epstein-Barr virus (EBV) and HIV infection are at increased risk compared to the general population. Treatment includes surgery, radiation therapy and chemotherapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hodgkin Lymphoma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development

history and latest news and press releases.

The Hodgkin Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 3, 53, 44, 5, 21, 4 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 7, 4, 3, 3 and 1 molecules, respectively.

Hodgkin Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma (Oncology).

The pipeline guide reviews pipeline therapeutics for Hodgkin Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Hodgkin Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Hodgkin Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Hodgkin Lymphoma (Oncology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Hodgkin Lymphoma (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Hodgkin Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand

business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Overview

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Companies Involved in Therapeutics Development

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Drug Profiles

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Discontinued Products

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Product Development Milestones

Featured News & Press Releases

Apr 11, 2022: Glenmark Specialty S.A. receives approval for conducting phase 1 clinical trial of its novel molecule GRC 54276 in patients with advanced solid tumors and Hodgkin's lymphoma

Apr 10, 2022: Affimed presents updated clinical data from phase 1/2 study of AFM13 precomplexed with cord blood-derived NK cells at AACR Annual Meeting

Dec 14, 2021: Tessa Therapeutics announces positive data from phase 2 trial of autologous CD30-CAR-T therapy (TT11) in relapsed or refractory classical hodgkin lymphoma at 2021 ASH Annual Meeting

Dec 12, 2021: Seagen announces preliminary results from phase 2 clinical trial of ADCETRIS (brentuximab vedotin) in novel combination of agents for patients with advanced stage classical hodgkin lymphoma

Dec 09, 2021: Affimed to host virtual investor call today to discuss treatment of CD30-positive lymphoma patients with cord blood-derived natural killer cells pre-complexed with innate cell engager AFM13

Dec 02, 2021: BeiGene announces inclusion in the China National Reimbursement Drug List (NRDL) of Tislelizumab in three new indications

Dec 02, 2021: Innovent and Lilly announce successful expansion of Sintilimab in China National Reimbursement Drug List to include three additional first-line indications

Nov 04, 2021: Seagen to highlight multiple ADCETRIS (brentuximab vedotin) data presentations at the upcoming 2021 American Society of Hematology (ASH) Annual Meeting

Nov 03, 2021: Tessa Therapeutics announces presentation of autologous cell therapy data at 2021 ASH Annual Meeting

Sep 27, 2021: ONO receives approval of Opdivo (nivolumab) for dosage and administration for treatment of Pediatric Patients with Recurrent or Refractory Classical Hodgkin Lymphoma in Japan

Aug 30, 2021: Ligand's partner Gloria Biosciences receives approval in China for zimberelimab for the treatment of recurrent or refractory classical Hodgkin's lymphoma

Jun 22, 2021: ADC Therapeutics announces encouraging interim results from pivotal phase 2 clinical trial of Camidanlumab Tesirine (Cami) presented at the 16th Annual International Conference on Malignant Lymphoma

Jun 09, 2021: ADC Therapeutics announces presentation on Camidanlumab at the 16th Annual International Conference on Malignant Lymphoma

May 26, 2021: ADC Therapeutics announces online publication of Camidanlumab Tesirine phase 1 results in The Lancet Haematology

May 14, 2021: Tessa Therapeutics announces positive, topline data from ongoing phase 1 trial of allogeneic, "Off-the-Shelf" cell therapy, in patients with relapsed or refractory CD30-positive lymphoma

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by AbbVie Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by ADC Therapeutics SA, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Adlai Nortye Biopharma Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Affimed GmbH, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Alfasigma SpA, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Angiocrine Bioscience Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Apollomics Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Astellas Pharma Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by AstraZeneca Plc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Aurigene Discovery Technologies Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Avipep Pty Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Bayer AG, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by BeiGene Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Bio-Path Holdings Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Bristol-Myers Squibb Co,

2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Carrick Therapeutics Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Catalent Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Collectar Biosciences Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Cellectis SA, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Celleron Therapeutics Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Cellestia Biotech AG, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Cellular Biomedicine Group Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Celularity Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Checkmate Pharmaceuticals Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Checkpoint Therapeutics Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Chimeric Therapeutics Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by CSL Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by CStone Pharmaceuticals Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Curis Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Daiichi Sankyo Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Dyadic International Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Eutilex Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Faron Pharmaceuticals Oy, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Genentech USA Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Gibson Oncology LLC, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Gilead Sciences Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Glenmark Pharmaceuticals Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Guangzhou Sinogen Pharmaceutical Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Hangzhou Sumgen Biotech Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Harbin Gloria Pharmaceuticals Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Hebei Senlang Biotechnology Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Helocyte Biosciences Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by HRAIN Biotechnology Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Hutchison MediPharma Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Immune Cell Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Incyte Corp, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Inhibrx Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Innovent Biologics Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Intellia Therapeutics Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Kymera Therapeutics Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by LegoChem Biosciences Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Luye Pharma Group Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Magenta Therapeutics Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Marker Therapeutics Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by MediSix Therapeutics Pte Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Merck & Co Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Merck KGaA, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Millennium Pharmaceuticals Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Miltenyi Biotec BV & Co KG, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Mirati Therapeutics Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by NewBio Therapeutics Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Northlake International LLC, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by OncoTartis Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Ono Pharmaceutical Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Pfizer Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by PlantForm Corp, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Protheragen Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Rafael Pharmaceuticals Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by RAPT Therapeutics Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Regeneron Pharmaceuticals Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Rhizen Pharmaceuticals SA, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Rich Pharmaceuticals Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Rizen (Suzhou) Biosciences Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Sanofi, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Seagen Inc, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Shanghai First Song Therapeutics Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Shanghai Pharmaceutical Group Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Shanghai Pharmaceuticals Holding Co Ltd, 2022

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Shanghai Unicar-

Therapy Bio-Medicine Technology Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Shanghai YaKe
Biotechnology Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Shattuck Labs Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Shenzhen Chipscreen
Biosciences Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Sichuan Kelun
Pharmaceutical Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by SpecificiT Pharma Inc,
2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Suzhou Everhealth
Biomedical Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Syndax Pharmaceuticals
Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Tacitus Therapeutics Inc,
2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Takeda Pharmaceutical
Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Tessa Therapeutics Ltd,
2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Tevogen Bio Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Tubulis GmbH, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Tyme Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Vincerx Pharma Inc,
2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Viracta Therapeutics Inc,
2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Waterstone Hanxbio Pty
Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Wuhan Bio-Raid
Biotechnology Co Ltd, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Xencor Inc, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects, 2022
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/H13E0C1F162AEN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H13E0C1F162AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

